title: MAGE-A family expression is correlated with poor survival of patients with lung adenocarcinoma: a retrospective clinical study based on tissue microarray.
abstract: OBJECTIVE
  As the best characterised cancer/testis antigen family members, melanoma-associated antigens (MAGE) have been reported to be expressed in various malignant tumours. However, the expression pattern of MAGE-A family in lung adenocarcinoma (LAC) specimens and their prognostic and therapeutic significance for patients with LAC is still unclear.
  
  
  METHODS
  Tissue microarray-based immunohistochemistry analysis was used to examine the expression of MAGE-A family members (including MAGE-A1, A2, A3, A4, A6, A10, A11 and A12) in 105 paired LAC specimens and the corresponding pericarcinoma specimens. The association between MAGE-A expression and the clinicopathological parameters, and the 10-year overall survival of patients with LAC were analysed. In addition, the association between MAGE-A expression and the epithelial growth factor receptor (EGFR) amplification and ALK-EML4 rearrangements of patients with LAC were also analysed.
  
  
  RESULTS
  The immunohistochemical evaluation revealed that MAGE-A family was expressed in 46.66% of LAC specimens, but not in the corresponding pericarcinoma specimens. MAGE-A expression was not associated with the clinicopathological factors but with worse 10-year survival, and was a poor prognostic marker for patients with LAC. MAGE-A expression was not correlated with EGFR amplification and ALK rearrangements. Interestingly, MAGE-A expression can affect the overall survival of patients with LAC without EGFR amplification or ALK rearrangements, but not affect the overall survival of patients with LAC and EGFR amplification or ALK rearrangements.
  
  
  CONCLUSIONS
  Molecular assessment of MAGE-A family members could be considered to improve the prognostic evaluation and to provide a new potential therapeutic strategy for patients with LAC.
authors.affiliation: Research Center, the Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, People's Republic of China.|Tumor Research Institute, the Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, People's Republic of China.
authors.forename: Meixiang
authors.initials: M
authors.lastname: Sang
authors.affiliation: Research Center, the Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, People's Republic of China.
authors.forename: Lina
authors.initials: L
authors.lastname: Gu
authors.affiliation: Research Center, the Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, People's Republic of China.
authors.forename: Danjing
authors.initials: D
authors.lastname: Yin
authors.affiliation: Research Center, the Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, People's Republic of China.
authors.forename: Fei
authors.initials: F
authors.lastname: Liu
authors.affiliation: Research Center, the Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, People's Republic of China.
authors.forename: Yishui
authors.initials: Y
authors.lastname: Lian
authors.affiliation: Research Center, the Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, People's Republic of China.|Clinical Laboratory, Julu County Hospital, Xingtai, Hebei, People's Republic of China.
authors.forename: Xiaochong
authors.initials: X
authors.lastname: Zhang
authors.affiliation: Research Center, the Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, People's Republic of China.
authors.forename: Shina
authors.initials: S
authors.lastname: Liu
authors.affiliation: Research Center, the Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, People's Republic of China.
authors.forename: Weina
authors.initials: W
authors.lastname: Huang
authors.affiliation: Research Center, the Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, People's Republic of China.
authors.forename: Yunyan
authors.initials: Y
authors.lastname: Wu
authors.affiliation: Research Center, the Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, People's Republic of China.|Tumor Research Institute, the Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, People's Republic of China.
authors.forename: Baoen
authors.initials: B
authors.lastname: Shan
mesh_terms: D000230:Adenocarcinoma / Q000235:genetics / Q000401:mortality*; D000077192:Adenocarcinoma of Lung; D000328:Adult; D000368:Aged; D000077548:Anaplastic Lymphoma Kinase; D014408:Biomarkers, Tumor / Q000235:genetics / Q000378:metabolism*; D018797:Cell Cycle Proteins / Q000235:genetics; D066246:ErbB Receptors / Q000235:genetics / Q000378:metabolism; D005260:Female; D015321:Gene Rearrangement; D006801:Humans; D053208:Kaplan-Meier Estimate; D008175:Lung Neoplasms / Q000235:genetics / Q000401:mortality*; D008207:Lymphatic Metastasis; D008297:Male; D058950:Melanoma-Specific Antigens / Q000235:genetics / Q000378:metabolism*; D008869:Microtubule-Associated Proteins / Q000235:genetics; D008875:Middle Aged; D009363:Neoplasm Proteins / Q000235:genetics / Q000378:metabolism*; D011379:Prognosis; D020794:Receptor Protein-Tyrosine Kinases / Q000235:genetics; D012189:Retrospective Studies; D012697:Serine Endopeptidases / Q000235:genetics; D046888:Tissue Array Analysis
chemical_list: D014408:Biomarkers, Tumor; D018797:Cell Cycle Proteins; D058950:Melanoma-Specific Antigens; D008869:Microtubule-Associated Proteins; D009363:Neoplasm Proteins; C000626173:ALK protein, human; D000077548:Anaplastic Lymphoma Kinase; D066246:ErbB Receptors; D020794:Receptor Protein-Tyrosine Kinases; C415585:EML4 protein, human; D012697:Serine Endopeptidases
keywords: LUNG CANCER; TUMOUR BIOLOGY; TUMOUR MARKERS